Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
Big Cypress Acquisition Corp (NASDAQ: BCYP) has announced a Special Meeting on October 20, 2021, for stockholders to vote on a proposed business combination with SAB Biotherapeutics, a clinical-stage biopharmaceutical company focusing on innovative immunotherapies. The SEC has declared effective Big Cypress' Registration Statement to facilitate the transaction. If approved, SAB will become a public entity under the name SAB Biotherapeutics, Inc., with trading set to commence on Nasdaq under the symbols 'DIVR' and 'DIVRW.'
- Expected strategic merger with SAB Biotherapeutics, enhancing market position in biopharmaceuticals.
- SAB's innovative immunotherapy platform may lead to significant revenue growth.
- Approval is contingent upon stockholder votes, which could introduce uncertainty.
- Market reactions to the merger may vary depending on investor sentiment.
MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to, among other matters, allow its stockholders to approve the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc., (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. On September 22, 2021, the Securities and Exchange Commission ("SEC") declared effective Big Cypress' registration statement on Form S-4 (as amended, the "Registration Statement"), which includes a definitive proxy statement in connection with the Special Meeting of Big Cypress' stockholders. Big Cypress and SAB entered into a definitive agreement relating to the business combination on June 22, 2021, that would result in SAB becoming a public company upon the closing of the transaction.
The Special Meeting is scheduled to be held on October 20, 2021, at 10:00 a.m., Eastern Time, and will be conducted virtually via live webcast. Holders of record of Big Cypress' common stock at the close of business on the record date of September 17, 2021, may vote at the Special Meeting.
Upon the closing of the business combination, the combined company will be named SAB Biotherapeutics, Inc. (the "Combined Company"). The parties expect that the Combined Company's common stock and warrants will be listed on the Nasdaq Stock Exchange under the ticker symbols "DIVR" and "DIVRW," respectively.
Big Cypress stockholders who need assistance voting or have questions regarding the Special Meeting may contact Big Cypress' proxy solicitor, Kingsdale Advisors, by telephone toll-free at (800) 775-1986 or by email at contactus@kingsdaleadvisors.com. Banks and brokerage firms may call (416) 867-2272.
About Big Cypress Acquisition Corp.
Big Cypress Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses with a focus within the life sciences industry. Big Cypress is led by Chief Executive Officer, Chief Financial Officer and Director Samuel J. Reich. For more information, visit www.bigcypressaccorp.com.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: www.sabbiotherapeutics.com and follow @SABBantibody on Twitter.
Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the development of SAB-185, and the proposed business combination between Big Cypress and SAB. These statements are based on the current expectations of SAB and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB.
Additional Information and Where to Find It
Big Cypress has filed a Registration Statement on Form S-4 with the SEC, which includes a prospectus and proxy statement. Big Cypress intends to mail a definitive proxy statement/final prospectus and other relevant documents to its stockholders. This communication is not a substitute for the Registration Statement, the definitive proxy statement/final prospectus or any other document that Big Cypress will send to its stockholders in connection with the proposed business combination. Investors and security holders of Big Cypress are advised to read, when available, the proxy statement/prospectus in connection with Big Cypress' solicitation of proxies for its special meeting of stockholders to be held to approve the proposed business combination (and related matters) because the proxy statement/prospectus will contain important information about the proposed business combination and the parties to the proposed business combination. The definitive proxy statement/final prospectus will be mailed to stockholders of Big Cypress as of September 17, 2021. Stockholders will also be able to obtain copies of the proxy statement/prospectus, without charge, at the SEC's website http://www.sec.gov or by directing a request to ir@bigcypressaccorp.com.
Participants in the Solicitation
Big Cypress, SAB and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Big Cypress' stockholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed business combination of Big Cypress' directors and officers in Big Cypress' filings with the SEC including the Registration Statement that has been filed with the SEC by Big Cypress, which includes the proxy statement of Big Cypress for the proposed business combination, and such information and names of SAB's directors and executive officers also be in the Registration Statement submitted to the SEC by Big Cypress, which includes the proxy statement of Big Cypress for the proposed business combination.
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Big Cypress or SAB, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
Contact:
Big Cypress Acquisition Corp.
Barbara Lindheim
BLL Partners for Big Cypress
+1 917-355-9234
blindheim@bllbiopartners.com
View original content:https://www.prnewswire.com/news-releases/big-cypress-acquisition-corp-announces-special-meeting-of-stockholders-to-approve-business-combination-with-sab-biotherapeutics-301383620.html
SOURCE Big Cypress Acquisition Corp
FAQ
What is the purpose of the Special Meeting for Big Cypress (BCYP)?
When is the Special Meeting for Big Cypress (BCYP) shareholders?
What will happen if the merger between Big Cypress and SAB is approved?
What is SAB Biotherapeutics known for?
